ECM2

Across TCGA pan-cancer cohorts, ECM2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ECM2 data layer compared with 22 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher ECM2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ECM2 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

UCEC, HNSC, and LSCC are the cancer types where ECM2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Tertile	III,IV	0.366	1.000	.008	24	view →
HNSC	DFS	Median	III,IV	0.969	0.701	.004	10	view →
LSCC	OS	Quartile	All	0.756	0.938	.014	9	view →
CCRCC	DFS	Median	II,III,IV	0.052	1.000	.038	3	view →
PDAC	OS	Median	All	0.692	0.949	.011	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ECM2–UCEC (DFS)

Open the UCEC breakdown →